Cell death &differ:药物靶向鸟苷酸合成酶抑制黑色素瘤侵袭

2015-04-29 佚名 生物谷

生物谷BIOON/ --近日,国际学术期刊cell death &differentiation 在线发表了美国科学家的一项最新研究进展,他们发现单磷酸鸟苷酸合成酶(GMPS)在恶性黑色素瘤的侵袭转移过程中具有重要作用,同时他们还找到一种GMPS抑制因子可能对于恶性黑色素瘤细胞侵袭和成瘤能力具有重要抑制作用。   恶性黑色素瘤是由皮肤和其他器官黑素细胞产生的肿瘤,是人类肿

生物谷BIOON/ --近日,国际学术期刊cell death &differentiation 在线发表了美国科学家的一项最新研究进展,他们发现单磷酸鸟苷酸合成酶(GMPS)在恶性黑色素瘤的侵袭转移过程中具有重要作用,同时他们还找到一种GMPS抑制因子可能对于恶性黑色素瘤细胞侵袭和成瘤能力具有重要抑制作用。
 
恶性黑色素瘤是由皮肤和其他器官黑素细胞产生的肿瘤,是人类肿瘤中转移能力最强的肿瘤之一。许多研究表明获得侵袭能力是黑色素瘤转移的先决条件,所以了解黑色素瘤侵袭发生的分子机制对于设计黑色素瘤治疗干预药物具有非常重要的意义。
 
在该项研究中,研究人员发现鸟苷酸从头合成途径的关键酶--单磷酸鸟苷酸合成酶(GMPS)对于来源于人类转移性黑色素瘤的BRAFv600e或NRASq61r突变细胞的侵袭和成瘤能力具有非常重要的作用。并且相比于良性黑色素瘤,GMPS的表达水平在人类转移性黑色素中显著增加,这表明GMPS可能是抗黑色素瘤治疗方法的潜在靶向目标。狭霉素A是由Streptomyces hygroscopius产生的一种核苷类似物能够抑制GMPS活性,在这项研究中,研究人员首次发现狭霉素A能够有效抑制黑色素瘤细胞的侵袭和成瘤能力。
 
这项研究表明GMPS是增强黑色素瘤细胞侵袭的重要驱动因子,同时还证明狭霉素a可能通过GMPS抑制黑色素瘤细胞侵袭和成瘤,但需要进一步研究验证这一发现。

原始出处:

A Bianchi-Smiraglia1, J A Wawrzyniak1, A Bagati1, E K Marvin1, J Ackroyd2, S Moparthy1, W Bshara3, E E Fink1, C E Foley1, G E Morozevich4, A E Berman4, D S Shewach2 and M A Nikiforov1.Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.Cell Death & Differentiation, April 24, 2015.doi: 10.1038/cdd.2015.47

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811371, encodeId=c49318113e1ba, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Jan 26 09:17:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869094, encodeId=b00b186909468, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 22 17:17:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959345, encodeId=897c19593454c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 04 10:17:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680285, encodeId=2a30168028517, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 11 00:17:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784199, encodeId=49511e841993e, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Dec 24 08:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531389, encodeId=bd63153138982, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558700, encodeId=194d1558e00af, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564709, encodeId=c54a1564e09b9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811371, encodeId=c49318113e1ba, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Jan 26 09:17:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869094, encodeId=b00b186909468, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 22 17:17:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959345, encodeId=897c19593454c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 04 10:17:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680285, encodeId=2a30168028517, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 11 00:17:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784199, encodeId=49511e841993e, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Dec 24 08:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531389, encodeId=bd63153138982, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558700, encodeId=194d1558e00af, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564709, encodeId=c54a1564e09b9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1811371, encodeId=c49318113e1ba, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Jan 26 09:17:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869094, encodeId=b00b186909468, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 22 17:17:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959345, encodeId=897c19593454c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 04 10:17:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680285, encodeId=2a30168028517, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 11 00:17:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784199, encodeId=49511e841993e, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Dec 24 08:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531389, encodeId=bd63153138982, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558700, encodeId=194d1558e00af, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564709, encodeId=c54a1564e09b9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2015-08-04 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1811371, encodeId=c49318113e1ba, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Jan 26 09:17:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869094, encodeId=b00b186909468, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 22 17:17:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959345, encodeId=897c19593454c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 04 10:17:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680285, encodeId=2a30168028517, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 11 00:17:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784199, encodeId=49511e841993e, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Dec 24 08:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531389, encodeId=bd63153138982, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558700, encodeId=194d1558e00af, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564709, encodeId=c54a1564e09b9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2016-02-11 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1811371, encodeId=c49318113e1ba, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Jan 26 09:17:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869094, encodeId=b00b186909468, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 22 17:17:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959345, encodeId=897c19593454c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 04 10:17:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680285, encodeId=2a30168028517, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 11 00:17:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784199, encodeId=49511e841993e, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Dec 24 08:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531389, encodeId=bd63153138982, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558700, encodeId=194d1558e00af, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564709, encodeId=c54a1564e09b9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2015-12-24 isabellayj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1811371, encodeId=c49318113e1ba, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Jan 26 09:17:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869094, encodeId=b00b186909468, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 22 17:17:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959345, encodeId=897c19593454c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 04 10:17:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680285, encodeId=2a30168028517, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 11 00:17:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784199, encodeId=49511e841993e, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Dec 24 08:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531389, encodeId=bd63153138982, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558700, encodeId=194d1558e00af, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564709, encodeId=c54a1564e09b9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2015-05-01 cy0328
  7. [GetPortalCommentsPageByObjectIdResponse(id=1811371, encodeId=c49318113e1ba, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Jan 26 09:17:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869094, encodeId=b00b186909468, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 22 17:17:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959345, encodeId=897c19593454c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 04 10:17:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680285, encodeId=2a30168028517, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 11 00:17:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784199, encodeId=49511e841993e, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Dec 24 08:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531389, encodeId=bd63153138982, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558700, encodeId=194d1558e00af, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564709, encodeId=c54a1564e09b9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1811371, encodeId=c49318113e1ba, content=<a href='/topic/show?id=38628e90472' target=_blank style='color:#2F92EE;'>#药物靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87904, encryptionId=38628e90472, topicName=药物靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Jan 26 09:17:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869094, encodeId=b00b186909468, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 22 17:17:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959345, encodeId=897c19593454c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 04 10:17:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680285, encodeId=2a30168028517, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 11 00:17:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784199, encodeId=49511e841993e, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Dec 24 08:17:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531389, encodeId=bd63153138982, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558700, encodeId=194d1558e00af, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564709, encodeId=c54a1564e09b9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri May 01 00:17:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]

相关资讯

百时美免疫组合Opdivo+Yervoy一线治疗黑色素瘤获巨大成功

百时美施贵宝(BMS)近日公布了备受业界关注的免疫组合疗法Opdivo+Yervoy用于黑色素瘤一线治疗的积极顶线数据。与Yervoy单药疗法相比,Opdivo+Yervoy组合疗法取得了非常高的客观缓解率(61% vs 11%),完全缓解率22%,疾病恶化或死亡风险降低60%,疗效之强劲在黑色素瘤治疗领域前所未有。业界认为,该方案将为晚期黑色素瘤提供一个极其重要的一线治疗选择,再次证明了不同

免疫疗法引领抗癌革命

这位49岁的女士之前在自己的皮肤上去除了3个黑色素瘤,但现在病情正在进一步扩散。她左乳下一个数厘米大小的肿瘤已经深入到胸壁当中。肿瘤上的一些组织正因缺少血流而死亡。纪念斯隆-凯特琳癌症中心(Memorial Sloan Kettering Cancer Center)的医生向她提供了实验性的两种药物组合治疗方案:Opdivo和Yervoy,它们均由百时美施贵宝(Bristol-Myers Sq

Nature Genet:转座子突变分析发现黑色素瘤驱动基因

近日,国际学术期刊nature genetics在线发表了美国科学家的一项最新研究进展,他们发现sleeping beauty(SB)转座子造成的突变能够促进BRAFv600e突变小鼠黑色素瘤的发生,同时还发现了1232个可能驱动黑色素瘤发生的候选癌基因。   黑色素瘤是一种转移性极高的恶性皮肤肿瘤,其发生可能受到环境和基因的共同影响。在黑色素瘤中,BRAFv600e是一个重要的

Lancet Oncology:Ipilimumab延长晚期黑色素瘤术后患者生存期

最新发表在The Lancet Oncology杂志上的关于EORTC试验的研究结果显示,Ipilimumab辅助治疗显著延长高危复发型III期黑色素瘤手术切除后患者的无复发生存期,但这种治疗也与几种不良事件发生率的提高有关。当前,黑色素瘤10年存活率低于10%,据估计美国每年有超过8000人是死于这种疾病的。除临床试验所使用的方法外,针对黑色素瘤的标准治疗方法是细胞毒性的化疗,一般为30年前FD

NEJM:两个免疫治疗联合药物成功使恶性黑色素瘤消失

 “纽约一分钟”是一个美国标语,意味着非常短暂或极度压缩的时间。它恰好可以描述最近发生在纽约斯隆•凯德琳癌症纪念研究中心的黑色素瘤病人的治疗反应。一位患有转移性黑色素瘤的49岁女病人,左胸下有一个具大有蒂的坏死性肿瘤,在进行一个剂量的试验性结合免疫治疗3周后,肿瘤消失了。肿瘤消失的程度和速度是难以置信的, 4月20日发表于NEJM上的MSK的三名临床医生书信中写道。 “这是我见

Lancet Oncology:对抗CTLA-4药物治疗后进展的黑色素瘤疗效对比,Nivolumab V.S 化疗

PD-1是一种细胞周期检验点蛋白,它的失控导致肿瘤细胞能够逃避体内免疫监控。Nivolumab是人类IgG4 PD-1免疫检查点抑制剂抗体,通过抑制细胞表面的PD-1蛋白而起作用,这种蛋白会阻断体内免疫系统对肿瘤细胞的攻击。Opdivo用于先前接受过ipilimumab治疗的黑色素瘤患者,以及携带BRAFV600突变的患者,在接受ipilimumab以及一种BRAF抑制剂治疗之后使用。这个由施贵宝